ABOS
Acumen Pharmaceuticals Inc
2.20$
-3.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | – | – | – | – | |
| 505.4% | 556.9% | 856.9% | – | – | – | – | |
| -405.4% | -456.9% | -856.9% | – | – | – | – | |
| 505.4% | 556.9% | 856.9% | – | – | – | – | |
| 54.6% | 94.1% | 506.9% | – | – | – | – | |
| 54.6% | 94.1% | 506.9% | – | – | – | – | |
| -459.9% | -551.0% | -1,363.8% | – | – | – | – | |
| 0.0% | 0.0% | 5,642.2% | – | – | – | – | |
| -465.9% | -510.1% | -7,006.0% | – | – | – | – | |
| -2.7% | -0.1% | 5,645.8% | – | – | – | – | |
| -465.9% | -510.1% | -7,006.0% | – | – | – | – | |
| 7.0% | -551.0% | -7,005.7% | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.